Azathioprine and Pemphigus Vulgaris

Burton, J.L.

doi:10.1001/archderm.1973.01620240070024

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

2021

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Azathioprine has been recommended as the first corticosteroidsparing agent for patients with PV for over 20 years, 8,9,35,36 thus allowing historically high complete remission rates (28-45%) and low mortality rates (1.4-7%) with corticosteroid-only treatment. 3,[37][38][39][40] However, AE such as leukopenia may lead to life-threatening infections that result in treatment discontinuation. For nearly 40 years, TPMT has been considered the most relevant gene in AZA-induced leukopenia.…”

Section: Discussionmentioning

confidence: 99%

Effect of NUDT15 polymorphisms on early hematological safety of low‐dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study

Zhou

Cheng

Wang

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

Pemphigus vulgaris (PV) is an acquired autoimmune disease, characterized by erythema, loose blisters, and erosions found to occur on the mucosa and skin. 1,2 In the early 1950s, approximately 75% of patients with PV reportedly died within a year. 3 Following the introduction of corticosteroid treatment, the mortality rate decreased to 15-45%. In the late 1960s, researchers observed that the combined

show abstract